Search

Your search keyword '"Bittner, V. A."' showing total 183 results

Search Constraints

Start Over You searched for: Author "Bittner, V. A." Remove constraint Author: "Bittner, V. A."
183 results on '"Bittner, V. A."'

Search Results

1. Two of a kind: mass and molar immunoassay-based lipoprotein (a) concentrations are similarly prognostic for MACE risk and predictive of alirocumab benefit in ODYSSEY OUTCOMES

3. Recurrent atherosclerotic cardiovascular disease events preventable with guideline recommended lipid-lowering treatment following myocardial infarction

4. Lipoprotein(a) and the effect of alirocumab on coronary and non-coronary revascularization following acute coronary syndrome

5. Longer-term safety of alirocumab with 24,610 patient-years of placebo-controlled observation: further insights from the ODYSSEY OUTCOMES trial

7. Relation of Lipoprotein(a) Levels to Incident Type 2 Diabetes and Modification by Alirocumab Treatment

8. Effect of alirocumab on lipoprotein(a) and cardiovascular risk after acute coronary syndrome

10. Persistent chest pain at 1-year predicts long-term angina hospitalization in women with and without obstructive coronary artery disease: results from Women's Ischemia Syndrome Evaluation (WISE)

14. 4115Effect of alirocumab on recurrent cardiovascular events after acute coronary syndrome, according to the intensity of background statin treatment

17. Psychotropic medication use and risk of adverse cardiovascular events in women with suspected coronary artery disease: outcomes from the Women's Ischemia Syndrome and Evaluation (WISE) study

24. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome

26. Predicted Versus Observed Major Adverse Cardiac Event Risk in Women with Evidence of Ischemia and No Obstructive Coronary Artery Disease: A Report from Women’s Ischemia Syndrome Evaluation (WISE)

27. Cardiovascular Outcomes With Alirocumab After Acute Coronary Syndrome: Results of the Odyssey Outcomes Trial

30. Use of High-Intensity Statin Therapy Post-Acute Coronary Syndrome in the Ongoing ODYSSEY OUTCOMES Trial of Alirocumab, A Proprotein Convertase Subtilisin/Kexin type 9 Monoclonal Antibody, Versus Placebo: Interim Baseline Data

31. Reduction of dioxygen catalyzed by pyrene-wired heme domain cytochrome P450 BM3 electrodes

32. Risk of heart failure and death after prolonged smoking cessation: Role of amount and duration of prior smoking

35. Prognostic value of global MR myocardial perfusion imaging in women with suspected myocardial ischemia and no obstructive coronary disease: results from the NHLBI-sponsored WISE (Women's Ischemia Syndrome Evaluation) study

36. Effects of right ventricular ejection fraction on outcomes in chronic systolic heart failure

44. Vliv epikondylární pásky na viskoelastické vlastnosti měkkých tkání u diagnózy tenisový loket.

46. Referral patterns to a University-based cardiac rehabilitation program.

47. Adherence to National Cholesterol Education Program Treatment goals in postmenopausal women with heart disease. The Heart and Estrogen/Progestin Replacement Study (HERS). The HERS Research Group.

48. Prediction of mortality and morbidity with a 6-minute walk test in patients with left ventricular dysfunction. SOLVD Investigators.

Catalog

Books, media, physical & digital resources